EurekAlert!

Study concludes primary IGF-1 deficiency is a frequent cause of short stature

Data presented by UCLA researcher Dr. Pinchas Cohen at the Pediatric Academic Societies' 2005 annual meeting in Washington, D.C., demonstrated that non-growth hormone deficient primary insulin-like ...
Business Wire

Tercica Launches Increlex in the U.S.; Only Drug Approved for the Long-Term Treatment of Growth Failure Caused by Severe Primary IGFD

BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 3, 2006--Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin ...
Healio

High-dose mecasermin increases growth rates in patients with IGF-1 deficiency

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mecasermin, when administered at the highest end of the ...
EurekAlert!

Tercica launches Increlex in the US

Tercica, Inc. (Nasdaq:TRCA) today announced the U.S. commercial launch of Increlex(TM) (mecasermin (rDNA origin) injection), the only recombinant human insulin-like growth factor-1 (rhIGF-1) ...
Nature

Near-Adult Height Outcomes in Patients Treated With rhIGF-1 for Severe Growth Failure: Real-World IGFD Registry Data

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...